|
Long-Term Effects of Ranitidine on Cancer Development
|
|
Several years ago, the FDA asked manufacturers to remove products containing ranitidine from the U.S. market, pointing to potential cancer risks related to a known human carcinogen that was an ingredient in many of them. Now, a new study has identified no difference in cancer risk for patients who used ranitidine compared with other histamine-2 receptor antagonists. Read more.
|
|
|
Semaglutide Reduces Symptom Burden in HFpEF
|
|
|
Heart failure with preserved ejection fraction (HFpEF) is increasing in prevalence and is associated with a high symptom burden and functional impairment, especially in the obese. Yet, no specific therapies have been approved to treat it. Find out why a new study suggests that therapy with semaglutide, originally approved for type 2 diabetes treatment, might be valuable for patients with HFpEF.
|
|
Bridge Program Provides Free COVID-19 Shots for Uninsured
|
|
|
New COVID-19 booster vaccines have been recommended just as cases of SARS-CoV-2 infections and hospitalizations are continuing to rise across the United States. Find out how the Bridge Access program works and how it might lead to a more permanent program for adults who are uninsured or only partly insured for COVID-19 and therapeutics.
|
|
|
Increasing Therapeutic Errors Among Pediatric ADHD Medications
|
|
There has been a substantial increase in the number of therapeutic errors related to attention-deficit/hyperactivity disorder (ADHD) medications serious enough to be reported to poison control centers—partly because so many more adolescents and children have been diagnosed over the past 2 decades. Errors have increased in both out-of-hospital and inpatient settings, according to a new report published in Pediatrics. Read more.
|
|
.jpg)
